淋巴结转移与胰头导管腺癌术后预后关系的回顾性队列研究

doi:10.11952/j.issn.1007-1954.2018.03.010

摘要/Abstract

摘要：

[摘要] 目的 探讨淋巴结转移对胰头导管腺癌胰十二指肠切除术后预后的影响。方法提取美国SEER数据库2004年1月至2013年12月共6 549例诊断为胰头导管腺癌且行胰十二指肠切除术的患者临床病理数据，回顾性分析淋巴结转移情况与预后的关系。结果共有6 549例患者入选，患者1、3、5年癌症相关生存率分别为73%、29%、19%，中位生存时间为21个月。单因素分析显示，患者性别、年龄、分化程度、肿瘤直径、侵袭范围、是否淋巴结转移、淋巴结转移数、淋巴结检出数、淋巴结阳性率（P<0.05）与预后相关，人种、婚姻状态与预后无统计学相关性（P>0.05）。多因素Cox回归分析显示，患者性别、年龄、分化程度、肿瘤直径、侵袭范围、淋巴结检出数、淋巴结阳性率与预后相关（P<0.05）。无淋巴结转移的患者5年癌症相关生存率31%，中位生存期为29.7个月；淋巴结转移的患者5年癌症相关生存率14%，中位生存期为19.1个月，差异有统计学意义（P<0.05）。淋巴结检出数＜15个时患者5年癌症相关生存率17%，中位生存期为20.3个月，淋巴结转移率为62.9%；淋巴结检出数≥15个时患者5年癌症相关生存率20%，中位生存期为22.0个月，淋巴结转移率为78.0%，差异有统计学意义（P<0.05）。进行分层分析时，无论是否有淋巴结转移，淋巴结检出数增加可显著改善预后（P<0.05）。5年癌症相关生存率随着淋巴结阳性率升高而降低（P<0.05）。结论胰头导管腺癌患者淋巴结转移情况与预后密切相关，淋巴结检出数、淋巴结阳性率是其预后的独立影响因素。

关键词: 胰头导管腺癌, 预后, 淋巴结转移, , 癌症相关生存率

Abstract:

Abstract objective To explore the impact of lymph node metastasis on the prognosis of patients with pancreatic head duct adenocarcinoma after pancreatoduodenectomy. Methods The clinical and pathological data of 6 549 patients who diagnosed with pancreatic head ductal adenocarcinoma, and then undergone pancreatoduodenectomy, were extracted from Jan. 2004 to Dec. 2013 by American SEER database. The
relationship between lymph node metastasis and prognosis was analyzed retrospectively. Results A total of 6549 patients were selected. The 1, 3, and 5- year cancer specific survival rates were 73%, 29% and 19%, and the median survival time was 21 months. Univariate analysis showed that gender, age, degree of differentiation, tumor size, invasion range, whether lymph node metastasis (LNM) present or not, number of lymph node metastasis (nLNM), lymph node examined (LNE), lymph node positive rate (LNR) (P<0.05) were correlated with the prognosis, regardless of race, marital status (P>0.05). Multivariate Cox regression analysis showed that gender, age, differentiation, tumor size, invasive range, whether LNM present or not, LNE, LNR were correlated with prognosis (P<0.05). The 5- year cancer specific survival rate of patients without lymph node metastasis was 31%, the median survival time was 29.7 months; and the 5- year cancer specific survival rate of lymph node metastasis patients was 14%, the median survival time was 19.1 months, the difference was statistically significant (P<0.05). If LNE < 15, the 5-year cancer specific survival was 17%, the median survival time was 20.3 months, and the lymph node metastasis rate was 62.9%; if LNE ≥ 15, the 5-year cancer specific survival was 20%, the median survival time was 22.0 months, and the lymph node metastasis rate was 78.0%; the difference was statistically significant (P<0.05). In the stratified analysis, no matter whether lymph node metastasis or not, the increase in the number of LNE improved prognosis significantly (P<0.05). The 5- year cancer specific survival rate decreased with the increase of LNR (P<0.05). Conclusion For patients with pancreatic head ductal carcinoma, LNM was closely correlated with prognosis. In addition, factors including LNE, LNR were independent prognosis factors for patients with pancreatic head ductal carcinoma.

Key words: pancreatic head ductal adenocarcinoma, , prognosis, , lymph nodes metastasis, , cancer specific sur-vival rate

中图分类号:

R735.9

李皇保, 周俊, 吴晓俊, 闵捷, 赵凤庆, 刘文, 黎亮, 于费杰, 陈帅. 淋巴结转移与胰头导管腺癌术后预后关系的回顾性队列研究[J]. 肝胆胰外科杂志, 2018, 30(3): 221-226.

LI Huang-bao, ZHOU Jun, WU Xiao-jun, MIN Jie, ZHAO Feng-qing, LIU Wen, LI Liang, YU Fei-jie, CHEN Shuai.. A retrospective cohort study on the relationship between lymph node metastasis and postoperative prognosis of pancreatic head ductal carcinoma[J]. Journal of Hepatopancreatobiliary Surgery, 2018, 30(3): 221-226.

参考文献

相关文章 15

[1]	徐晓飞, 陈敏江, 纪建松. 影像组学在肝细胞癌研究中的应用进展 [J]. 肝胆胰外科杂志, 2024, 36(1): 59-64.
[2]	丁兢, 邸亮, 李聪, 赵晓飞, 郭庆良, 马超. 术前血清VEGF和IL-12水平对原发性肝癌腹腔镜肝切除术预后的影响[J]. 肝胆胰外科杂志, 2023, 35(8): 459-463.
[3]	朱坤忠, 张跃伟. 胰腺癌肝转移介入治疗的研究进展 [J]. 肝胆胰外科杂志, 2023, 35(8): 507-512.
[4]	范祺, 倪彦彬, 高杰, 朱继业, 李照. 原发性肝癌术后复发再次肝切除的疗效分析 [J]. 肝胆胰外科杂志, 2023, 35(7): 390-396.
[5]	杨木易, 俞鹏, 胡雄伟, 洪智贤. 血清γ-GT及CA199评估肝内胆管细胞癌切除术后预后的价值[J]. 肝胆胰外科杂志, 2023, 35(6): 343-347.
[6]	蔡慧欣, 项思博, 杨文军. VAVs基因家族在肝癌中的表达及临床意义[J]. 肝胆胰外科杂志, 2023, 35(6): 366-373.
[7]	蒋弟, 陈诚, 刘智鹏, 王子然, 刘雲华, 刘兴超, 樊海宁, 白洁, 江艳, 陈志宇. 肝门部胆管癌根治性切除术后教科书式结局发生的预测因素分析[J]. 肝胆胰外科杂志, 2023, 35(5): 263-267.
[8]	王进峰, 邓顺, 贺卓, 肖科, 吕品, 马铁祥, 费书珂, 刘卓, 徐彪铭, 王双, 罗建红, 欧阳永忠, 谢江波, 郑金海, 李清龙, 左朝晖. 根治性顺行模块化胰脾切除术在胰体尾部癌中的应用(多中心研究) [J]. 肝胆胰外科杂志, 2023, 35(3): 140-145.
[9]	王开东, 王雷, 刁先坪, 陆冠一, 范向军. 急性胆囊炎并发胆囊及肝脏破裂出血一例 [J]. 肝胆胰外科杂志, 2023, 35(3): 184-186.
[10]	易波, 杨召铭, 唐才喜, 赵志坚. 可切除或交界可切除胰腺癌新辅助治疗+手术与直接手术治疗的临床对比 [J]. 肝胆胰外科杂志, 2023, 35(2): 96-100.
[11]	申雪晗, 周江敏, 张志伟, 陈孝平. NLR对TACE联合仑伐替尼及免疫治疗的中晚期肝癌患者预后的预测价值[J]. 肝胆胰外科杂志, 2023, 35(1): 19-24.
[12]	陈晹, 万来忆, 朱益军, 李叶晟, 刘娇, 张猛, 曾东, 冯艳玲, 黄杨卿. 合并HIV感染肝细胞癌肝切除的回顾性分析—单中心7年数据总结[J]. 肝胆胰外科杂志, 2022, 34(9): 519-525.
[13]	孙聚珊, 王智鹏, 曹助, 张龙华, 白磊, 李涛, 赵晋明, 何翼彪. 肝移植术后早期发生胰岛素抵抗的危险因素[J]. 肝胆胰外科杂志, 2022, 34(9): 543-549.
[14]	杜岩, 姜文凯, 李昕, 周文策. KPNA4在胰腺癌中高表达并且与不良预后相关[J]. 肝胆胰外科杂志, 2022, 34(8): 488-494.
[15]	李睿哲, 薛军帅, 杨龙山, 董兆如, 洪建国, 李涛, 王东旭. 构建“免疫相关lncRNA基因对”模型预测未发生远处转移的原位肝癌预后及药物敏感性[J]. 肝胆胰外科杂志, 2022, 34(7): 406-413.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed